Compare TG Therapeutics Inc (TGTX) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs TKO Group Holdings Inc — how do they compare? TG Therapeutics Inc trades at $55.14 (market cap $8.16B), while TKO Group Holdings Inc trades at $179 (market cap $13.28B). The key difference: TKO Group Holdings Inc is the larger of the two by market cap, and TKO Group Holdings Inc pays a 1.74% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and TKO Group Holdings Inc for 30 Days on average.
| TGTX | TKO | |
|---|---|---|
Market Cap | $8.16B | $13.28B |
Volume | 1,735,121 | 857,653 |
Sector | Health | Media |
52-Week High | $59.06 | $224.96 |
52-Week Low | $26.94 | $175.58 |
Typical Hold Time | 16 Days | 30 Days |
Enterprise Value | $8.37B | $17.64B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
TKO trades at $179.38, up 0.41% on the day, but technical indicators signal a bearish trend with the stock near a 52-week low of $174.58 (Defense World, 2026-10-02). The company reported mixed Q2 2026 earnings, missing EPS estimates but raising full-year guidance. Revenue growth remains solid, with 2026 projections at $5.3B, though profitability margins are thin at 4.33% net income margin. A quarterly dividend of $0.79 was declared for payment in September 2026.
Wall Street maintains a bullish stance with 89% buy ratings and a $227 consensus price target, implying significant upside. Key risks include execution on media rights deals, competitive pressures in sports entertainment, and reliance on live events. The stock's high P/E of 63.73 suggests growth expectations must be met to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
